In a significant development for diabetes treatment in the U.S., Dr. Reddy’s Laboratories has unveiled its Saxagliptin and Metformin Hydrochloride Extended-Release Tablets. This launch introduces a therapeutic equivalent to the widely prescribed KOMBIGLYZE XR (saxagliptin and metformin hydrochloride extended release) tablets, with the endorsement of the US Food and Drug Administration (FDA).

The Indian pharmaceutical giant is supplying these tablets in varying strengths to cater to diverse patient needs. Specifically, the 2.5 mg/1000 mg strength comes in a 60-count bottle, while the 5 mg/500 mg and 5 mg/1000 mg strengths are available in 30-count bottles. The introduction of this generic version by Dr. Reddy’s Laboratories signals a significant step in offering cost-effective diabetes management options for American patients.

  Diabetes, Diabetes management, Dr. Reddy’s Laboratories, KOMBIGLYZE XR, Metformin, Saxagliptin, US FDA, US Food and Drug Administration, USA